However, no research to date has examined whether it protects peoples brains from traumatic brain injury or stroke
The trend towards cost-effective, decentralized solutions is expected to further propel the interventional segments expansion
Regulatory status: unapproved and research-use-only As of the preparation of this article, BPC-157 has not received marketing authorization from the US Food and Drug Administration, the European Medicines Agency, or equivalent national regulators for any therapeutic indication
The safety profile was acceptable, with gastrointestinal side effects being the most common, consistent with amylin analogues
: , ( I, II, III) () 10 15% ( ) 1720% :